Good Lifestyle

While thousands of Americans rush to getVaccinated against CovidData reported by a pharmaceutical company caused concerns with its non-approved vaccine. It was announced Monday 22 that the AstaZeneca-Oxford Covid vaccine - which has already been administered across the United States and other countries around the world, 100% effective against hospitalizations and serious illnesses in its clinical trials. But now, these conclusions have been questioned. Read to find out why national health institutes (NIH) question the results of the company and for more information on COVID vaccines.Do not do that within 2 weeks of your Covid vaccine, doctors warn.

AstraZeneca announced the result of its US trial on Monday, which included 32,449 participants, two-thirds of whomreceived two doses of the vaccine With four weeks between doses. The results claimed that the vaccine was 79% efficient to prevent the symptoms of COVID. The data also revealed that the vaccine was 100% effective in the prevention of hospitalization and serious illness.

"This analysis validates the AstaZeneca Covid-19 vaccine as a very necessary additional vaccination option, offering confidence that adults of all ages can benefit from virus protection"Ann FalseyMD, Professor of Medicine and Main Senior Investigator for the tests, said in a statement.

And for more information on the shot that leaves you with fewer side effects, checkThis Covid vaccine has the lowest rate of side effects, data emissions.

NIH (NIAID) National Institute of Allergies and Infectious Diseases (NIAID) revealed in a statement Tuesday that its data monitoring and security group (DSMB) - Independent Group within NIH, which reviews clinical studies - Ainterviewed the information Liberated by Astrazeneca. According to a press release, Niaid, an Advanced Research and Biomedical Development Authority (BARDA), and AstraZeneca have been contacted regarding Covid-19 vaccine clinical trial information that was initially published.

"The DSMB has expressed concern that AstaZeneca may have included obsolete information from this trial, which may have offered an incomplete vision of efficiency data," read the statement. "We urge the company to work with the DSMB to review efficiency data and ensure that the most accurate and up-to-date efficiency data is made public as quickly as possible."

Like all other vaccines approved in the United States-of Moderna, Pfizer and Johnson & Johnson - Authorization and Guidelines for the use of the Astrazeneca vaccine in the United States will be decided by the Food and Drug Administration (FDA) and centers of Disease control and prevention (CDC). But as it will happen, it remains now to see. And for more COVID updates,Sign up for our daily newsletter.

"That's really what you call an impartial mistake. Because the fact is: it's most likely a very good vaccine, and that kind of thing does ... nothing reallydoubt on vaccines, "Niaid DirectorAnthony Fauci, MD, says about ABCHello AmericaTuesday.

"If you look at it, the data is pretty good, but when they put it in the press release, it was not completely accurate," he explained. The DSMB "wrote a rather hard note To them and with a copy for me to say that, they felt that the data found in the press release were somewhat obsolete and that it could actually mislead a little and wanted them to recover. "

Less than 12 hours after NIH revealed their apprehension for data, AstraZeneca released a statement on published numbers on Monday. Thepharmaceutical companyThe data was "based on pre-specified intermediate analysis with a data cut of February 17".

AstraZeneca said they now carry out a statistical analysis of the data to confirm the effectiveness of vaccination. "We will immediately participate in the Independent Commission for Data Security Monitoring (DSMB) to share our first analysis with the most up-to-date efficacy data," said Astrazeneca. "We intend to issue results from the main analysis within 48 hours."

And for more new vaccines up-to-date,That's why half of people have lighter vaccine side effects, says CDC.

The use of the AstaZeneca vaccine had been temporarily suspended by several European countries on the concerns that caused blood clots. After the European Medicines Agency (EMA) conducted an investigation andExcluded a clear link between shot and blood clotting On March 18, most countries have since resumed the deployment of the vaccine.

AstraZeneca said the DSMB conducted a specific examination of potential coagulation problems and found no data that concerned them. "The DSMB has found no increased risk of thrombosis or events characterized by thrombosis," the Astrazeneca press release said.

And if you plan to get vaccinated at any time soon,Do not do it two hours before or after your vaccine, doctors warn.